William Pao

Q: What Schools Are Affiliated With William Pao

William Pao is affiliated with the following schools: University of Cologne, Nagoya City University, University of California, Los Angeles, National Taiwan University, Universiti Teknologi Petronas, Washington University in St. Louis, Yale University, Swinburne University of Technology Sarawak Campus, Vanderbilt University, Stanford University, University of Manchester, Fudan University, Harvard University

William Pao's AcademicInfluence.com Rankings

William Pao

Medical

#1141

World Rank

#1451

Historical Rank

Oncology

#85

World Rank

#89

Historical Rank

medical Degrees

William Pao

Biology

#4443

World Rank

#6622

Historical Rank

Molecular Biology

#789

World Rank

#809

Historical Rank

biology Degrees

Download Badge

Medical
Biology

William Pao's Degrees

Doctorate Medicine Stanford University
PhD Molecular Biology Stanford University

Why Is William Pao Influential?

(Suggest an Edit or Addition)

According to Wikipedia, William Pao is an oncologist and Executive Vice President and Chief Development Officer of Pfizer. He was previously the head of Pharma Research and Early Development at Roche and a professor of medicine at the Vanderbilt University Medical Center. He is best known for his work in molecular oncology and cancer genomics.

(See a Problem?)

William Pao's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2005) (3427)
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. (2004) (3411)
Comprehensive genomic characterization of squamous cell lung cancers (2012) (2998)
Somatic mutations affect key pathways in lung adenocarcinoma (2008) (2640)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers (2013) (2004)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing (2012) (1620)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (2007) (1619)
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. (2014) (1463)
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. (2014) (1364)
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (2005) (1226)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer (2012) (1151)
Characterizing the cancer genome in lung adenocarcinoma (2007) (1122)
New driver mutations in non-small-cell lung cancer. (2011) (1085)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010) (984)
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009) (870)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer (2010) (841)
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors (2006) (807)
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. (2004) (750)
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. (2010) (734)
Acquired resistance to TKIs in solid tumours: learning from lung cancer (2014) (721)
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib (2006) (709)
Syk tyrosine kinase required for mouse viability and B-cell development (1995) (664)
Anchored multiplex PCR for targeted next-generation sequencing (2014) (654)
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. (2007) (636)
ROS1 rearrangements define a unique molecular class of lung cancers. (2012) (617)
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. (2005) (610)
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. (2012) (598)
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation (2010) (570)
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay (2011) (547)
Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma (2008) (534)
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. (2013) (533)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. (2005) (532)
KRAS mutations in non-small cell lung cancer. (2009) (530)
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling (2011) (503)
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. (2009) (495)
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. (2006) (467)
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. (2012) (450)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase (2011) (425)
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. (2013) (424)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 (2012) (421)
A Genomics-Based Classification of Human Lung Tumors (2013) (403)
Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer (2006) (393)
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. (2009) (365)
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. (2014) (360)
Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond (2008) (352)
Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies (2010) (338)
New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer (2011) (333)
Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas (2007) (322)
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. (2010) (321)
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. (2011) (317)
EML4-ALK: honing in on a new target in non-small-cell lung cancer. (2009) (312)
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. (2008) (300)
Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus (2007) (297)
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia (2012) (277)
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. (2008) (263)
Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma (2008) (263)
Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. (2015) (258)
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers (2009) (257)
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer (2009) (254)
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. (2015) (253)
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. (2011) (253)
Genetic predictors of MEK dependence in non-small cell lung cancer. (2008) (252)
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. (2011) (248)
Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma (2008) (248)
Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. (2005) (242)
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 (2005) (241)
Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer (2014) (237)
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants (2012) (236)
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors (2009) (223)
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. (2006) (217)
Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method (2007) (217)
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. (2008) (212)
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer (2010) (212)
Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers (2011) (205)
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors (2016) (202)
Chipping away at the lung cancer genome (2012) (197)
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. (2011) (197)
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. (2012) (197)
Comprehensive Histologic Assessment Helps to Differentiate Multiple Lung Primary Nonsmall Cell Carcinomas From Metastases (2009) (194)
Practical management of patients with non-small-cell lung cancer treated with gefitinib. (2005) (193)
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). (2011) (190)
Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials (2012) (188)
EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. (2008) (185)
A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. (2011) (184)
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors (2011) (183)
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib (2008) (166)
Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis (2012) (163)
Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas (2009) (162)
Copper foam/PCMs based heat sinks: An experimental study for electronic cooling systems (2018) (161)
Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers (2013) (159)
Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. (2011) (159)
Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications (2009) (155)
BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition (2013) (149)
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas (2013) (139)
Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung Cancers (2009) (137)
High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507) (2009) (135)
Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. (2015) (133)
Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib (2011) (129)
Characteristics of Lung Cancers Harboring NRAS Mutations (2013) (126)
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations (2011) (126)
Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non alpha/beta" T cells (1996) (123)
Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. (2014) (123)
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). (2011) (118)
Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. (2010) (117)
FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer (2014) (117)
Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations (2011) (116)
Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors (2007) (114)
How genetically engineered mouse tumor models provide insights into human cancers. (2011) (114)
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer (2013) (113)
Intrathymic δ Selection Events in γδ Cell Development (1997) (110)
A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development (2010) (109)
Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping (2012) (108)
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy (2013) (103)
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer (2007) (101)
Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance (2012) (101)
Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives (2013) (100)
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. (2014) (100)
HER 2 Amplifi cation : A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFR T 790 M Mutation (2012) (99)
MET Exon 14 Skipping in Non-Small Cell Lung Cancer. (2016) (95)
A Bioinformatics Workflow for Variant Peptide Detection in Shotgun Proteomics* (2011) (95)
Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas (2010) (90)
Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains (2012) (89)
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer (2010) (88)
[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. (2010) (88)
Coupling temperature to a double‐porosity model of deformable porous media (2000) (87)
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma (2011) (87)
Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report (2010) (86)
Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4 (2007) (85)
Integration of Molecular Profiling into the Lung Cancer Clinic (2009) (85)
γδ T cell help of B cells is induced by repeated parasitic infection, in the absence of other T cells (1996) (85)
A fully coupled hydro‐thermo‐poro‐mechanical model for black oil reservoir simulation (2001) (83)
A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance (2014) (83)
Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib (2011) (81)
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. (2017) (80)
Translating genomic information into clinical medicine: Lung cancer as a paradigm (2012) (79)
Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. (2010) (79)
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. (2016) (78)
Phase II study of gefitinib treatment in advanced thymic malignancies (2005) (78)
A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer (2006) (78)
Three-dimensional finite element simulation of three-phase flow in a deforming fissured reservoir (2002) (77)
Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer (2012) (75)
Facilitating a culture of responsible and effective sharing of cancer genome data (2016) (75)
A protein knockdown strategy to study the function of β-catenin in tumorigenesis (2003) (74)
Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients. (1989) (73)
Constitutive activation of Raf-1 induces glioma formation in mice. (2008) (73)
Genetically informed lung cancer medicine (2011) (70)
Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase. (1996) (70)
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells (2015) (69)
Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. (2010) (69)
A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). (2013) (68)
Thermal Comfort Analysis of PMV Model Prediction in Air Conditioned and Naturally Ventilated Buildings (2015) (66)
Patterns and processes of somatic mutations in nine major cancers (2014) (66)
Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never‐smoking women in Asia: a report from the female lung cancer consortium in Asia (2015) (64)
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). (2004) (64)
Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations (2010) (63)
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. (2014) (63)
Primary extracranial neuroblastoma with central nervous system metastases characterization by clinicopathologic findings and neuroimaging (1991) (62)
Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer (2011) (60)
Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies (2014) (59)
Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib (2011) (59)
Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance (2003) (59)
Targeted therapies: Afatinib—new therapy option for EGFR-mutant lung cancer (2013) (58)
Postoperative radiotherapy in the treatment of extremity soft tissue sarcomas. (1990) (57)
Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene (2011) (56)
ACTIVITY OF AFATINIB/CETUXIMAB IN PATIENTS (PTS) WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AND ACQUIRED RESISTANCE (AR) TO EGFR INHIBITORS (2012) (55)
Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer. (2018) (54)
Phase change material/heat pipe and Copper foam-based heat sinks for thermal management of electronic systems (2020) (53)
CFD Method for Predicting Annular Pressure Losses and Cuttings Concentration in Eccentric Horizontal Wells (2014) (52)
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance (2013) (50)
Analysis of Major Known Driver Mutations and Prognosis in Resected Adenosquamous Lung Carcinomas (2014) (49)
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors (2016) (48)
MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis (2014) (47)
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. (2009) (47)
A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. (2014) (47)
EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. (2006) (46)
Fully coupled modeling of seabed subsidence and reservoir compaction of North Sea oil fields (2003) (46)
Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies (2017) (43)
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. (2016) (43)
Numerical Simulation of Three-Phase Flow in Deforming Fractured Reservoirs (2002) (41)
Primary gamma delta cell clones can be defined phenotypically and functionally as Th1/Th2 cells and illustrate the association of CD4 with Th2 differentiation. (1998) (41)
Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer (2010) (40)
Germinal center formation in mice lacking αβ T cells (1996) (40)
Finite element analysis and approximate estimation of the cross coupling effect in fractured reservoirs (2003) (38)
Oncogenes come of age. (2005) (38)
Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. (2016) (38)
NGS catalog: A database of next generation sequencing studies in humans (2012) (36)
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma (2015) (36)
Consensus Rules in Variant Detection from Next-Generation Sequencing Data (2012) (35)
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. (2013) (34)
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor (2015) (34)
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? (2004) (33)
Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. (2013) (33)
Serum levels of surfactant protein D are increased in mice with lung tumors. (2003) (33)
AACR Cancer Progress Report 2016 (2016) (32)
Alternative techniques for casting process simulation (2004) (31)
Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. (2015) (30)
Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer (2014) (30)
Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer (2011) (30)
A medical-axes-based interpolation method for solidification simulation (2004) (29)
Intrathymic delta selection events in gammadelta cell development. (1997) (29)
Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial (2007) (28)
Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC) (2005) (26)
Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases (2018) (26)
EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial (2005) (24)
Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types (2015) (24)
Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer: A Time for Excitement and Equipoise (2008) (24)
Numerical simulation of two-phase flow regime in horizontal pipeline and its validation (2018) (23)
Condensate retention as a function of condensate flow rate on horizontal enhanced pin-fin tubes (2019) (23)
Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204‐PDGFRB fusion in a patient with recurrent T‐ALL and an associated myeloproliferative neoplasm (2012) (23)
Coupled thermo-hydro-mechanical model with consideration of thermal-osmosis based on modified mixture theory (2013) (22)
Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. (2012) (22)
Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. (2014) (22)
Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients (2015) (21)
Unsaturated hydro-mechanical–chemical constitutive coupled model based on mixture coupling theory: Hydration swelling and chemical osmosis (2016) (21)
New approaches to targeted therapy in lung cancer. (2012) (21)
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling (2014) (20)
Prediction of phase separation in a T-Junction (2018) (20)
EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib (2012) (20)
Enhanced medial axis interpolation algorithm and its application to hotspot prediction in a mould–casting assembly (2005) (19)
EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. (2008) (19)
Effect of T-junction diameter ratio on stratified-wavy flow separation (2018) (19)
Influence of site of expression on the fetal gamma delta T-cell receptor repertoire. (1991) (19)
Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors (2017) (18)
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. (2010) (18)
Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma. (2013) (18)
Defining clinically relevant molecular subsets of lung cancer (2006) (18)
Predictive Biomarkers and Personalized Medicine Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer : Distinct Natural History of Patients with Tumors Harboring the T 790 M Mutation (2011) (17)
Experimental investigation on the effect of diameter ratio on two-phase slug flow separation in a T-Junction (2018) (17)
Experimental investigation of two-phase separation in T-Junction with combined diameter ratio (2020) (17)
Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy. (2006) (17)
BAC Consensus Conference, November 4–6, 2004: Epidemiology, Pathogenesis, and Preclinical Models (2006) (17)
Design of Helical Capacitance Sensor for Holdup Measurement in Two-Phase Stratified Flow: A Sinusoidal Function Approach (2016) (16)
Role of phase change materials thickness for photovoltaic thermal management (2022) (15)
A genetic algorithm for optimizing gravity die casting's heat transfer coefficients (2011) (15)
Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone (2015) (15)
Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib (2004) (15)
EGFR mutant lung cancer. (2012) (14)
Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers (2010) (14)
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. (2017) (14)
Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib. (2006) (14)
A review: Evolution of branching T-junction geometry in terms of diameter ratio, to improve phase separation (2021) (13)
A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers. (2015) (13)
Numerical simulation of two-phase separation in T-junction with experimental validation (2018) (13)
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer (Science Translational Medicine (2012) 4, (130er2)) (2011) (12)
Molecular on/off switch. (2006) (12)
Computer implementation of Heuvers' circle method for thermal optimisation in castings (2005) (12)
Modified Yield Power‐Law fluid flow in narrow annuli with inner rotating pipe (2015) (12)
Erlotinib in lung cancer. (2005) (12)
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma (2015) (12)
Numerical investigation of gas separation in T-junction (2015) (12)
A new target for therapy in squamous cell carcinoma of the lung. (2011) (11)
Surrogate reservoir modeling-prediction of Bottom-Hole Flowing Pressure using Radial Basis Neural Network (2014) (11)
DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment-A catalogue of clinically relevant somatic mutations in lung cancer. (2011) (11)
Germinal center formation in mice lacking alpha beta T cells. (1996) (10)
Predictive Biomarkers and Personalized Medicine Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T 790 M Mutation Using a Locked Nucleic Acid-Based Assay (2011) (10)
Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling. (2015) (10)
Acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer. (2006) (10)
Cancer Therapy : Preclinical See commentary by Crystal and Shaw , p . 4479 Differential Protein Stability and ALK Inhibitor Sensitivity of EML 4-ALK Fusion Variants (2012) (10)
Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI). (2010) (10)
Mathematical model of coupled dual chemical osmosis based on mixture-coupling theory (2018) (10)
EGFR mutation, immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC (2005) (10)
My Cancer Genome: Web-based clinical decision support for genome-directed lung cancer treatment. (2011) (9)
A REVIEW OF T-JUNCTION GEOMETRICAL EFFECT ON TWO-PHASE SEPARATION (2016) (9)
ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. (2012) (9)
Expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). (2009) (9)
9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC) (2011) (9)
Maximizing the benefits of off-target kinase inhibitor activity. (2013) (9)
Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome. (2014) (8)
Erosion–Corrosion of 30°, 60°, and 90° Carbon Steel Elbows in a Multiphase Flow Containing Sand Particles (2019) (8)
Numerical investigation of smoke contamination in atrium upper balconies at different down stand depths (2017) (8)
T Cell Receptor, γδ (1998) (8)
Numerical simulation of two–phase separation in a small diameter ratio T‐junction (2017) (8)
Numerical evaluation of separation efficiency in the diverging T-junction for slug flow (2021) (8)
Numerical simulation of two-phase slug flow with liquid carryover in different diameter ratio T-junction (2017) (8)
Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. (2010) (8)
Dynamic Well Bottom-Hole Flowing Pressure Prediction Based on Radial Basis Neural Network (2014) (8)
Computational Analyses of Passive Wet Gas Separation in Branched Piping (2014) (7)
Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). (2009) (7)
A prospective study to correlate EGFR mutations with gefitinib response (2005) (7)
Effect of Different Qualities of Foam on Fill Particle Transport in Horizontal Well Cleanup Operation Using Coiled Tubing (2014) (7)
Hodgkin's disease in children. (1989) (7)
Fill removal from horizontal wellbore using foam in different coiled tubing/annulus diameter ratios (2015) (7)
Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib. (2004) (7)
Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistancein vitro. (2013) (7)
Local-regional non-rhabdomyosarcomatous soft tissue sarcomas of the head and neck. (1990) (6)
A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations. (2009) (6)
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma. (2010) (6)
Numerical Investigation of Sand Particle Erosion in Long Radius Elbow for Multiphase Flow (2019) (6)
Acquired resistance to epidermal growth factor receptor (EGFR) kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma (2008) (6)
PRELIMINARY NUMERICAL SIMULATION OF STEADY-STATE GAS-LIQUID FLOW IN HORIZONTAL T-JUNCTION (2017) (6)
Horizontal Well Cleanup Operation Using Foam in Different Coiled Tubing/Annulus Diameter Ratios (2014) (6)
Influence of Sand Fines Transport Velocity on Erosion-Corrosion Phenomena of Carbon Steel 90-Degree Elbow (2020) (6)
O-109 Phase II trial of erlotinib in patients with bronchioloalveolarcarcinoma (2005) (6)
SIMULATION OF TWO PHASE OIL-GAS FLOW IN T-JUNCTION (2016) (6)
The NIH-led research response to COVID-19 (2023) (6)
Assessment of Different Matrix-fracture Shape Factor in Double Porosity Medium (2013) (6)
Effect of Sand Fines Concentration on the Erosion-Corrosion Mechanism of Carbon Steel 90° Elbow Pipe in Slug Flow (2020) (6)
A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC). (2011) (6)
Numerical validation of gas-liquid slug flow inside horizontal pipe (2018) (5)
Instability and reaction-diffusion transport of bacteria (2004) (5)
Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: Is timing important? (2005) (5)
Modelling of pressure drop in eccentric narrow horizontal annuli with the presence of cuttings and rotating drillpipe (2015) (5)
Clinical Practice Guideline Update on Chemotherapy for Stage IV Non – Small-Cell Lung Cancer (2009) (5)
Numerical analyses for improved hydrodynamics of deep water torpedo anchor (2015) (5)
Numerical investigation and prediction of phase separation in diverging T-junction (2022) (5)
Numerical Investigation of the Elbow Angle Effect on Solid Particle Erosion for Liquid-Solid Flow (2019) (5)
CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment (2016) (5)
Influence of site of expression on the fetal yv T-cell receptor repertoire (4)
JAK 2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors (2016) (4)
Catalyzing the field of precision oncology, one basket at a time (2018) (4)
Estimation of the likelihood of epidermal growth factor receptor (EGFR) mutations based on cigarette smoking history in patients with adenocarcinoma of the lung (2005) (4)
Clinical Applications of Kinase Inhibitors in Solid Tumors (2010) (4)
Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer (2010) (4)
Further advances in genetically informed lung cancer medicine. (2013) (4)
Abstract B10: Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291. (2014) (4)
Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib (2005) (4)
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors : Tissue Analysis fromNorth (2005) (4)
The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor. Authors' reply (2007) (4)
Erratum: BAC Consensus Conference, November 4-6, 2004: Epidemiology, pathogenesis, and preclinical models (Journal of Thoracic Oncology (2006) 1, (S2-S7)) (2007) (4)
Review of Factors Affecting the Phase-Redistribution in the Branching T-Junction (2021) (4)
Preliminary Results of Numerical Simulation of Slug Flow in a Regular T-Junction (2018) (4)
SIMULATION OF TWO PHASE OIL-GAS FLOW IN PIPELINE (2016) (4)
Numerical evaluation of separation efficiency in converging T-junction with slug flow (2019) (3)
A Review: Factors Affecting Internal Two-Phase Flow-Induced Vibrations (2022) (3)
In-situ Stress Perturbation due to Temperature around Borehole during Carbon Injection (2013) (3)
Optimization of Insulation Padding for Directional Solidification (2013) (3)
Numerical analyses for improved terminal velocity of deep water torpedo anchor (2017) (3)
Disruption of epithelial y6 T cell repertoires by mutation of the Syk tyrosine kinase (2005) (3)
Experimental investigation of multiphase separation in different flow regimes through T-junction with an expander section (2019) (3)
Numerical Study of Water Control with Downhole Oil-Water Separation Technology (2014) (3)
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib. (2022) (3)
Two-phase slug flow separation at T-junction with regular and reduced vertical side arm (2018) (3)
Modelling of Pressure Drop and Cuttings Concentration in Eccentric Narrow Horizontal Wellbore with Rotating Drillpipe (2014) (3)
D2-01: Prospective trial of preoperative gefitinib to correlate response with EGFR exon 19 and 21 mutations and to select patients for adjuvant gefitinib (2007) (3)
MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis (2014) (3)
Wilms' tumor: reduced-dose radiotherapy in advanced-stage Wilms' tumor with favorable histology. (1990) (3)
Numerical Investigation of Liquid Carryover in T-Junction with Different Diameter Ratios (2018) (3)
Clinical and pathologic characteristics of patients with PI3K-mutant breast cancers. (2013) (3)
Experimental study on the impact of wet sand particle to the erosion of carbon steel and HDPE (2018) (3)
Epidermal growth factor receptor mutations detected in tumors from Chinese "never smokers" with lung adenocarcinoma. (2005) (3)
Rapamycin prevents the development and progression of mutant EGFR lung tumors with the acquired resistance mutation T790M (2014) (3)
Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC). (2013) (3)
A Unified Adaptive Fanger's Model for Thermal Comfort in Tropical Countries (2013) (3)
Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E) (2014) (3)
Abstract 1788: Preclinical development of a selective, potent small molecule ALK inhibitor (2010) (3)
466PTARGETING RESISTANCE IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC): PRECLINICAL EVIDENCE SUPPORTING THE COMBINATION OF EGFR TYROSINE KINASE INHIBITORS (TKIS) AZD9291 AND GEFITINIB WITH MOLECULARLY TARGETED AGENTS AND IMMUNOTHERAPEUTICS. (2014) (3)
Numerical Investigation on the Effect of Down Stand Structure in Fire Compartment on Smoke Contamination Atrium Upper Balconies (2013) (2)
Drilling Parameter Effects on Cuttings Transport in Horizontal Wellbores: A Review (2015) (2)
Numerical Validation of Two-Phase Slug Flow and its Liquid Holdup Correlation in Horizontal Pipeline (2017) (2)
Effect of Down Stand Depth Variation on Atriums Upper Balconies Smoke Contamination (2014) (2)
Pulse-continuous dose erlotinib as initial targeted therapy for patients with EGFR-mutant lung cancers with untreated brain metastases. (2017) (2)
HER2 Amplifi cation: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR (2012) (2)
A Preliminary Numerical Investigation of Thermal Mixing Efficiency in T-Junctions with Different Flow Configurations (2021) (2)
Dynamic Surrogate Reservoir Model with well constraints (2016) (2)
Melanoma BRAF Fusions—Response (2014) (2)
Prediction of Bottom-Hole Flowing Pressure using general regression neural network (2014) (2)
Therapeutics , Targets , and Chemical Biology Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors (2011) (2)
Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. (2010) (2)
Combining Expert Formula and Geometric Feature Extraction for Die Design (2013) (2)
Cuttings-liquid frictional pressure loss model for horizontal narrow annular flow with rotating drillpipe (2015) (2)
Numerical Investigation of the Effect of Square and Sinusoidal Waves Vibration Parameters on Heat Sink Forced Convective Heat Transfer Enhancement (2022) (1)
Simulation of Drill Pipe Lateral Vibration due to Riser's Oscillation (2013) (1)
Afatinib (A) plus cetuximab (C) in the treatment of patients (pts) with NSCLC : The story so far (2017) (1)
DESIGN AND DEVELOPMENT OF FANGER MODEL AND FUZZY LOGIC BASED CONTROLLER FOR AIR CONDITIONERS (2019) (1)
Abstract 5479: Somatic driver mutations among never smoking female lung cancer cases in China identify unique mutation pattern that may be associated with household coal burning (2012) (1)
Industry Corner: Perspectives and Controversies: Paradigms for the development of transformative medicines - lessons from the EGFR story. (2022) (1)
t(5;6)(q33-34;q23) CEP85L/PDGFRB (2013) (1)
Patterns and processes of somatic mutations in nine major cancers (2014) (1)
Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers (2013) (1)
Investigation of Maximum Erosion Zone in the Horizontal 90° Elbow (2020) (1)
Numerical investigation on the effect of balcony open and solid upstand on smoke contamination in atrium balconies (2017) (1)
Numerical simulation of three-phase flow in deforming three-dimensional fractured reservoirs (2001) (1)
Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors. (2011) (1)
Monitoring EGFR-mutant lung cancers by means of the blood. (2006) (1)
Integrated genomic analysis of lung adenocarcinomas identifies loss of the MAPK phosphatase gene DUSP4 in most EGFR mutant tumors (2007) (1)
Juliann Chmielecki with Evolutionary Cancer Modeling Small Cell Lung Cancer − Optimization of Dosing for EGFR-Mutant Non (2011) (1)
Experimental investigation of two-phase separation in a horizontal T-junction with vertical branch arm (2019) (1)
Characterizing Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in an EGFR Mutant Lung Adenocarcinoma Cell Line (2013) (1)
Routine multiplexed mutational analysis of colorectal cancers (CRCs): A single-institution experience. (2015) (1)
SENSITIVITY ANALYSIS OF CONCAVE CAPACITANCE SENSORS FOR HOLDUP MEASUREMENT IN TWO-PHASE FLOW (2016) (1)
Investigation on Erosion Due to Fine Particles in Multiphase Flow (2018) (1)
From academia to industry: a road more travelled. (2017) (1)
Simulation study on impact of fine sand particle to 90° steel elbow in pipe (2018) (1)
Abstract 1897: RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer (2012) (1)
454PPRE-CLINICAL AND CLINICAL EVALUATION OF AZD9291, A MUTATION-SPECIFIC INHIBITOR, IN TREATMENT-NAïVE EGFR MUTATED NSCLC. (2014) (1)
CO2 flow in saline aquifer with salt precipitation (2016) (1)
Abstract 1722: Investigating resistance to AZD9291 (2014) (1)
Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung (2005) (1)
51 – Biology of Lung Cancer (2016) (1)
Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC. (2019) (1)
A medial-axes-based interpolation method for solidi ! cation simulation (2003) (1)
Abstract PR04: BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. (2013) (1)
Flow Profile Distribution in Narrow Annuli Using Modified Yield Power-Law Fluid Model (2015) (0)
Abstract 2836: Rapamycin prolongs overall survival and progression-free survival in a mouse model of lung cancer in never smokers resistant to erlotinib (2011) (0)
Sinusoid based calibration for holdup measurement in two-phase flow using helical capacitance sensor (2016) (0)
Abstract LB-236: Identifying novel kinase fusions via targeted DNA capture and next-generation sequencing (2011) (0)
Disruption ofepithelial y6T cellrepertoires bymutation ofthe Syktyrosine kinase (antigen receptor generearrangement/lymphocyte development/tissue compartmentalization/Rag2Syk chimeras) (1996) (0)
Abstract PR05: ERK pathway activation is associated with acquired resistance to AZD9291, a third-generation irreversible inhibitor targeting EGFR sensitizing (EGFRm+) and resistance (T790M) mutations in NSCLC (2015) (0)
Numerical investigation on the effect of fire compartment opening width and heat release rate on the horizontal projection of smoke plume in a full-scale atrium (2018) (0)
Somatic mutation spectrum of non-small cell lung cancers (NSCLCs) from African Americans (AAs). (2012) (0)
J NEOPLASMS OF THE LUNG 51 BIOLOGY OF LUNG CANCER (2015) (0)
Abstract 768: A kinome-wide siRNA screen identifies modifiers of sensitivity to the EGFR T790M-targeted tyrosine kinase inhibitor (TKI), AZD9291, in EGFR mutant lung adenocarcinoma (2015) (0)
Surrogate Reservoir Model for Average Reservoir Pressure (2016) (0)
Objective Radiographic Response to MEK Inhibitor Therapy in a Patient with a Metastatic Melanoma with a BRAF (2012) (0)
IN THE SPOTLIGHT Maximizing the Benefi ts of Off-Target Kinase Inhibitor Activity (2013) (0)
Numerical Coupling of Drilling Vibration to Riser’s Oscillation (2014) (0)
A Study Examining Coupled Geomechanics and Reservoir Fluid Flow Modeling (2011) (0)
BAC consensus conference, November 4-6, 2004 (2006) (0)
Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib (2008) (0)
and Illustrate the Association of CD4 with Th2 Cells Phenotypically and Functionally as Th1/Th2 Cell Clones Can Be Defined δ γ Primary (2017) (0)
Abstract 731: Nuclear factor-κB activation and cetuximab-resistance in HNSCC cell lines (2011) (0)
PD5-3-7: EGFR and KRAS mutations are molecular predictors of survival in resected lung adenocarcinoma (2007) (0)
Next-generation sequencing (NGS)-based profiling of pancreatic acinar cell carcinoma for identification of a recurrent SND1-BRAF fusion. (2014) (0)
Abstract 956: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas (2014) (0)
Abstract A18: A novel targeted capture and massively parallel sequencing platform for systematic discovery of tyrosine kinase fusions in cancer (2010) (0)
The Epidermal Growth Factor Receptor D761Y Mutation and Effect of Tyrosine Kinase Inhibitor (2007) (0)
A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients. (2012) (0)
ponse Evaluation to Aid Biomarker Development (2010) (0)
Abstract PR16: Spatio-temporal heterogeneity in the tumor microenvironment influences the evolutionary dynamics of drug resistance (2015) (0)
Abstract 2417: A new mouse model for epithelial ear neoplasms based upon expression of mutant EGFRL858R/T790M (2011) (0)
Numerical simulation of two-phase fl ow regime in horizontal pipeline and its validation (2018) (0)
VARIOUS MATHEMATICAL MODEL OF TORSIONAL VIBRATION IN OILWELL DRILLSTRING AND THEIR VALIDATION TECHNIQUES (2016) (0)
Comprehensivegenomiccharacterization of squamous cell lung cancers (2012) (0)
Use of an Internet-based protocol to collect clinical information and blood from patients with lung cancer who never smoked cigarettes. (2009) (0)
Abstract C90: Dependence of afatinib and cetuximab resistant lung adenocarcinomas on mTOR signaling. (2013) (0)
Mutational analysis of EGFR signaling pathway genes in lung adenocarcinomas (2007) (0)
Abstract 4689: Inhibition of IL-6/Jak/Stat3 signaling: a novel and potent targeting therapy for lung cancer (2011) (0)
Smoking history and frequency of somatic KRAS mutations in adenocarcinoma of the lung (2007) (0)
Abstract 752: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas (2015) (0)
O-017 Lung adenocarcinomas with mutations in EGFR and KRAS havedistinct gene expression profiles (2005) (0)
Factors affecting fill removal from horizontal well during colied tubing cleanout operation (2014) (0)
O-123 A prospective study to correlate EGFR mutations with gefitinib response in early stage NSCLC (2005) (0)
Abstract 2438: Mechanisms of sensitivity and resistance to Sym004, a novel anti-EGFR antibody mixture, in EGFR mutant lung cancer. (2013) (0)
Abstract 1784: Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations (2010) (0)
Chinese scientists and US leadership in the life sciences (2019) (0)
resistance lines identifies spectrum of DNA changes associated with drug inhibitor-sensitive and-resistant EGFR mutant lung cancer cell Next-generation sequencing of paired tyrosine kinase Material Supplemental (2013) (0)
Wilm's tumor: analysis of reduced dose radiotherapy in stage iii abdominal disease with favorable histology (1989) (0)
Numerical investigation of smoke contamination in atrium upper balconies at different down stand depths (2016) (0)
Abstract 624: Synergistic effects of combining the Akt inhibitor triciribine with erlotinib in EGFR TKI-resistant NSCLC (2010) (0)
Numerical Methods in Simulation of Industrial Processes (2006) (0)
NovelD761YandCommonSecondary T790MMutationsinEpidermal Growth Factor Receptor^Mutant LungAdenocarcinomaswith AcquiredResistance toKinase Inhibitors (2006) (0)
Characteristics of NSCLCs harboring NRAS mutations. (2012) (0)
Abstract 231: Upregulation of HER3 (ErbB3) levels and function counteracts the antitumor effect of HER2 and PI3K inhibitors (2011) (0)
Abstract 4977: Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables discovery of a novel C6orf204-PDGFRβ fusion in a patient with T-ALL and eosinophilia (2011) (0)
Hydrate Formation in Two Phase Flow in Pipe (2016) (0)
T4 or MI? (2011) (0)
Evaluation of Relative Permeability Models in CO2/Brine System Using Mixed and Hybrid Finite Element Method (2016) (0)
Influence of Elbow Orientation on Solid Particle Erosion for Multiphase Flow (2020) (0)
Numerical investigation on the effect of channelled and unchannelled screens on smoke contamination in atriums upper balconies with open upstand (2017) (0)
Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer (2012) (0)
Elucidating Mechanisms of Sensitivity and Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer (2007) (0)
Predictive Biomarkers and Personalized Medicine Characteristics of Lung Cancers Harboring NRAS Mutations (2013) (0)
Fill Removal in Wellbore Using Coiled Tubing (2013) (0)
Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas (2012) (0)
Thermal and strength performance of reinforced self-compacting concrete slabs mixed with basalt and PVA fibers in high intensity fire (2017) (0)
Results of radiation therapy for retinoblastoma in children less than one year old (1989) (0)
EPHA2BlockadeOvercomesAcquired Resistance to EGFR Kinase Inhibitors in Lung Cancer (2016) (0)
Response to CCR-07-0070 (2007) (0)
Abstract 1774: Selection for the EGFR T790M gatekeeper resistance mutation may vary among different small molecule EGFR TKIs (2010) (0)
ProspectiveAssessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by theAddition of Everolimus (2007) (0)
Effects of Capillary Pressure on Multiphase Flow during CO2 Injection in Saline Aquifer (2014) (0)
Mutational profiling of the oncogenome in non-small cell lung cancer (NSCLC) (2005) (0)
Numerical Gas–Liquid Two-Phase Flow Regime Identification in a Horizontal Pipe Using Dynamic Pressure Data (2023) (0)
Abstract 5102: Identifying targets for melanoma therapy: Biological and clinical implications of BRAF L597 mutants (2012) (0)
Mutational and Clinicopathologic Characteristics of AdSqLCs (0)
Computer Simulation Investigation on the Effect of Channelled and Unchannelled Screens on Smoke Contamination in Atriums Upper Balconies (2014) (0)
Abstract 1106: Mechanism for activation of mutated EGF receptors in lung cancer. (2013) (0)
Aspects of Continuum Modelling of Multiphase Poroelasticity and Its Applications to North Sea Fields (2001) (0)
Abstract 933: Modeling acquired resistance to EGFR-directed therapies in mouse models of lung cancer. (2013) (0)
IA04 Early-Stage Drug Development in the 21st Century (2020) (0)
P-690 EGFR and KRAS mutational analysis of mucinous pneumonicbronchiololavelolar carcinomas (2005) (0)
250 Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes (2014) (0)
P1.01-25 Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles (2019) (0)
Adaptive and Open-based Model of Mobile Positioning Technology used in e-Transport System (2005) (0)
Modeling of Axial Spring Stiffness in Active Vibration Controlled Drilling (2014) (0)
Serum levels of surfactant protein D are increased in mice with lung tumors. (2003) (0)
Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies (2017) (0)
Capillary pressure and buoyancy effects in the CO2/brine flow system (2014) (0)
A preliminary study on well-based surrogate reservoir model (2013) (0)
Investigation of the liquid carryovers in the branching T-junction, based on historical data (2022) (0)
Abstract 3597: Experiences and lessons from innovative dose escalation designs in early-phase oncology (2017) (0)
Identifying strategies to enhance responses induced by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas (2007) (0)
Numerical study of gas-liquid flow maldistribution in a T-junction having very small diameter ratio (2017) (0)

This paper list is powered by the following services:

Other Resources About William Pao

en.wikipedia.org

What Schools Are Affiliated With William Pao?

William Pao is affiliated with the following schools:

William Pao's Academic­Influence.com Rankings

William Pao's Degrees

Why Is William Pao Influential?

William Pao's Published Works

Published Works

Other Resources About William Pao

What Schools Are Affiliated With William Pao?

William Pao's AcademicInfluence.com Rankings